Answers are grounded in this paper and cite their sources.
Summary Fed-batch bioprocesses are typically deployed to convert renewable feedstocks to bio-based products using metabolically engineered microorganisms. However, for low-value chemicals, fed-batch cultures provide insufficient volumetric productivity to yield commercially viable products. The greater overall volumetric productivity of continuous culture holds techno-economic promise, but the genetic instability of engineered strains has prevented commercial deployment. This study demonstrated the continuous bioproduction of citramalate (CMA) for over 1,000 h at a productivity of 0.32 gCMA gDCW−1 h−1. Plasmid segregational stability was ensured via infA-complementation, and structural stability was obtained under phosphate limitation in the chemostat. By contrast, glucose limitation promoted structural plasmid instability. Cost-prohibitive inducers were also avoided by using a constitutive promoter for gene expression. Plasmid-borne expression of CMA synthase delivered enhanced productivity compared to a chromosomal integrant strain also developed in this study. This work advances the techno-economic feasibility of sustainable chemicals manufacturing from renewable feedstocks by engineered strains in microbial cell culture.
No takes yet. Share an insight, caveat, or question.
Yiakoumetti et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: